Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026

뉴스 본문을 불러오고 있어요.

Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026 | 웨이프 WAPE

Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026

기사 요약

관련 종목

댓글 —